Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

Original reporting
Published Nov 17, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development — source image
Decision brief

The 30-second read

$ALZNBearishMed
01

Why it matters

FDA did not support broader eligibility criteria and indicated efficacy and safety trials may be more appropriate to support an NDA, prompting a trial pause and SOW termination. Management plans a Type B meeting and expects to move directly to a Phase III BD trial, while also targeting December 2026 final healthy-subject results and FDA feedback by end of Q2 2027.

02

Market read

This is a development-path disruption for ALZN, with FDA guidance and a paused trial that can materially affect perceived probability of success and timing to NDA.

03

What to watch

The article also notes a completed healthy-subject trial with final results expected in December 2026, which could partially offset timeline concerns if data are strong.

Relevance 7/10Novelty 7/10Timing: after-hours/next-session positioning ahead of the company’s December 2026 healthy-subject results and later FDA feedback

Background

Alzamend Neuro is developing AL001 for bipolar disorder; the company is revising its development plan after FDA feedback.

Company-level read

Ticker impact

$ALZNBearishHigh confidence
Context

Alzamend Neuro’s bipolar disorder BD trial was paused and its BD statement of work terminated as it seeks FDA guidance on a revised AL001 plan.

Expected impact

Likely downside pressure as investors price in slower timelines and higher probability of additional trial work before an NDA.

Evidence & confidence

The article cites a paused trial, terminated SOW, and FDA non-support for the proposed eligibility approach, plus a shift toward a Phase III plan after a Type B meeting.

Market effects

Highlights FDA scrutiny on trial design and eligibility criteria for CNS indications, which can weigh on sentiment for similar pre-NDA biotech programs.

No clear regional market linkage beyond US biotech risk appetite.

Limited, as the catalyst is company-specific FDA guidance and trial management.

Counterpoint

The pause and SOW termination could be viewed as a corrective step that improves the odds of an eventual NDA by aligning the program with FDA expectations.

Key entities

  • Alzamend Neuro, Inc.

    Subject of the SEC filing; paused its BD trial and is seeking FDA guidance on a revised AL001 development plan.

  • AL001

    Bipolar disorder candidate whose development plan is being revised following FDA feedback.

  • FDA

    Provided guidance rejecting broader eligibility criteria and suggesting efficacy and safety trials for NDA support.

  • MGH

    Terminated the BD statement of work after the trial was paused and will provide an approximately $25,000 refund.

Related articles

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.